The Centers for Medicare & Medicaid Services (CMS) has announced projected increases in Medicare Part D premiums and cost-sharing for 2026, affecting 56 million beneficiaries. These changes aim to balance drug affordability with plan sustainability, according to CMS data published this week.
Medicare Part D enrollment, premiums, and cost-sharing in 2026 reflect broader trends in prescription drug affordability and healthcare policy. With 56 million beneficiaries relying on outpatient drug coverage, shifts in plan design and pricing directly impact access to medications for older adults and people with disabilities. CMS data highlights a 5.2% average premium increase, alongside adjustments to deductibles and out-of-pocket maximums, underscoring the program’s evolving role in managing healthcare costs.
In Plain English: The Clinical Takeaway
- Premiums to rise slightly: Average monthly premiums are projected to increase by 5.2% in 2026, per CMS.
- Cost-sharing changes: Deductibles and out-of-pocket limits will vary by plan, with some offering enhanced coverage for high-cost drugs.
- Enrollment deadlines remain critical: Beneficiaries must enroll or switch plans during the Annual Election Period (Oct. 15–Dec. 7) to avoid gaps in coverage.
2026 Medicare Part D Changes: Clinical and Policy Context
CMS data reveals that the 2026 Medicare Part D program will see an average premium increase of 5.2%, driven by rising drug prices and expanded coverage for specialty medications. This aligns with a long-term trend of 3–7% annual premium growth since 2010, according to the Kaiser Family Foundation. The agency attributes the increase to “increased utilization of high-cost therapies and inflationary pressures in the pharmaceutical sector,” as stated in a press release.
Geographically, the impact of these changes varies. In the U.S., CMS collaborates with the Food and Drug Administration (FDA) to review drug formularies, ensuring that plans cover essential medications. For example, the FDA’s 2025 approval of a new class of GLP-1 receptor agonists for diabetes has prompted Part D plans to adjust coverage tiers, affecting patient out-of-pocket costs. Similarly, the National Institute for Health Care Management (NIHCM) notes that states with higher prescription drug spending, such as Florida and New York, may see more significant premium fluctuations due to regional drug pricing disparities.
Funding for CMS’s data collection and analysis comes from federal appropriations, with no direct industry sponsorship. The agency emphasizes that its projections are based on “actuarial models and historical claims data,” as outlined in its 2026 Part D Final Rule. However, critics argue that the lack of transparency in drug pricing negotiations between insurers and manufacturers limits the ability to predict long-term cost trends.
“The 2026 changes reflect a delicate balance between affordability and access,” said Dr. Sarah Collins, a health policy researcher at the University of Michigan. “While premiums are rising, many plans are expanding coverage for chronic disease medications, which could offset some costs for high-need patients.”
Peer-reviewed studies underscore the complexity of Medicare Part D’s impact. A 2023 JAMA study
